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Anxiolytic Effect of Melatonin in Premenstrual Dysphoric Disorder  
J.B. Santo, S. Lo, P. L'Espcirance, D.B. Boivin* 
Douglas Hospital Research Center, McGill University, Montreal, Que., Canada 
Increases in anxiety levels during the late-luteal phase of the menstrual cycle form important diagnostic 
criteria of premenstrual dysphoric disorder (PMDD) (1). Evidence exists to support the hypothesis that 
tolerance to endogenous levels of melatonin might occur during the luteal phase in PMDD (2, 3). It was 
hypothesized that slow release (SR) melatonin administration during the luteal phase of the menstrual 
cycle of participants with PMDD could significantly lower anxiety levels measured by self-report. 
Three participants (aged 32-41) diagnosed with PMDD were examined for a period of >6 menstrual 
cycles. Daily anxiety self-report scales ranging from 0 to 100 confirmed PMDD. After 3 menstrual cycles, 
participants were administered 2 mg SR melatonin 1 h prior to bedtime during the luteal phase for 3 
menstrual cycles. Mid-follicular (second week) and late-luteal (last week) scores were compared 
between baseline and treatment conditions using a Wilcoxon signed ranks test. 
 
Anxiety across the Menstrual Cycle 
 
 
Baseline anxiety was 19.76 (S.D.=24.57) during the mid-follicular phase and 41.23 (S.D.=33.84) during 
the late-luteal phase. This represents a 473% increase across the menstrual cycle (P< 0.0001). Treatment 
period anxiety levels during the late-luteal phase were 20.5 (S.D.=24.63), thus reduced to 50% of the 
baseline values of the luteal phase. Treatment period results from the late-luteal phase were 
comparable to those of the mid-follicular phase (P=0.523). 
Anxiety does vary significantly across the menstrual cycle in women with PMDD. Exogenous melatonin 
administration exerted a significant anxiolytic effect in participants. Whether melatonin administration 
counteracts a reduced activity of endogenous melatonin levels or rather exerts an independent 
pharmacological anxiolytic effect remains unclear. Despite these concerns, these results support the 
proposed hypothesis and suggest that reduced melatonin secretion and/or sensitivity may play a role in 
PMDD. A placebo trial and a control group is required to better understand the mediating factors 
involved. 
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